181 related articles for article (PubMed ID: 24384107)
1. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin.
Simpson SH; Abdelmoneim AS; Omran D; Featherstone TR
Am J Med; 2014 Jan; 127(1):95.e1-9. PubMed ID: 24384107
[TBL] [Abstract][Full Text] [Related]
2. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.
Simpson SH; Gamble JM; Mereu L; Chambers T
J Gen Intern Med; 2011 Nov; 26(11):1336-44. PubMed ID: 21647746
[TBL] [Abstract][Full Text] [Related]
3. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
Schnell O; Erbach M; Hummel M
Diab Vasc Dis Res; 2012 Oct; 9(4):245-55. PubMed ID: 22508698
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Bethel MA; Harrison P; Sourij H; Sun Y; Tucker L; Kennedy I; White S; Hill L; Oulhaj A; Coleman RL; Holman RR
Diabet Med; 2016 Feb; 33(2):224-30. PubMed ID: 26043186
[TBL] [Abstract][Full Text] [Related]
5. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
6. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review.
Bem D; Dretzke J; Stevens S; Lordkipanidzé M; Hodgkinson J; Bayliss S; Moore D; Fitzmaurice D
Syst Rev; 2015 Jun; 4():88. PubMed ID: 26088608
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
8. High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
Tobin WO; Kinsella JA; Coughlan T; Collins DR; O'Neill D; Murphy RP; Egan B; Tierney S; Feeley TM; McCabe DJ
Eur J Neurol; 2013 Feb; 20(2):344-52. PubMed ID: 22994699
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.
Nagatsuka K; Miyata S; Kada A; Kawamura A; Nakagawara J; Furui E; Takiuchi S; Taomoto K; Kario K; Uchiyama S; Saito K; Nagao T; Kitagawa K; Hosomi N; Tanaka K; Kaikita K; Katayama Y; Abumiya T; Nakane H; Wada H; Hattori A; Kimura K; Isshiki T; Nishikawa M; Yamawaki T; Yonemoto N; Okada H; Ogawa H; Minematsu K; Miyata T
Thromb Haemost; 2016 Aug; 116(2):356-68. PubMed ID: 27098431
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
Polzin A; Dannenberg L; Sophia Popp V; Kelm M; Zeus T
Platelets; 2016 Jun; 27(4):317-21. PubMed ID: 26556101
[TBL] [Abstract][Full Text] [Related]
11. Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature.
Lim ST; Coughlan CA; Murphy SJ; Fernandez-Cadenas I; Montaner J; Thijs V; Marquardt L; McCabe DJ
Platelets; 2015; 26(5):402-12. PubMed ID: 26042726
[TBL] [Abstract][Full Text] [Related]
12. [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
Legrand DA; Scheen AJ
Rev Med Liege; 2006 Oct; 61(10):682-90. PubMed ID: 17209500
[TBL] [Abstract][Full Text] [Related]
13. [Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Benhamou Y; Lévesque H
Rev Med Interne; 2009 Dec; 30(12):1001-3. PubMed ID: 19833416
[No Abstract] [Full Text] [Related]
14. Aspirin dose for prevention of cardiovascular disease in diabetics.
Nowak SN; Jaber LA
Ann Pharmacother; 2003 Jan; 37(1):116-21. PubMed ID: 12503945
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
16. Standard vs Modified Antiplatelet Preparation for Preventing Thromboembolic Events in Patients With High On-Treatment Platelet Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm: A Randomized Clinical Trial.
Hwang G; Huh W; Lee JS; Villavicencio JB; Villamor RB; Ahn SY; Kim J; Chang JY; Park SJ; Park NM; Jeong EA; Kwon OK
JAMA Neurol; 2015 Jul; 72(7):764-72. PubMed ID: 26010803
[TBL] [Abstract][Full Text] [Related]
17. [Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].
Legrand DA; Scheen AJ
Rev Med Liege; 2007 Oct; 62(10):610-5. PubMed ID: 18069572
[TBL] [Abstract][Full Text] [Related]
18. [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
Legrand DA; Scheen AJ
Rev Med Suisse; 2006 Aug; 2(76):1904-8. PubMed ID: 16972540
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet therapy: controversial aspects.
Coccheri S
Thromb Res; 2012 Mar; 129(3):225-9. PubMed ID: 22119155
[TBL] [Abstract][Full Text] [Related]
20. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Sacco M; Pellegrini F; Roncaglioni MC; Avanzini F; Tognoni G; Nicolucci A;
Diabetes Care; 2003 Dec; 26(12):3264-72. PubMed ID: 14633812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
